Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Piper Sandler to Hold Rating
Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) was upgraded by equities researchers at Piper Sandler to a “hold” rating in a research report issued on Wednesday, Marketbeat.com reports. The firm currently has a $3.00 price objective on the stock. Piper Sandler’s price objective suggests a potential upside of 5.63% from the company’s previous close. Separately, […]
More Stories
When Your Payment Provider Can No Longer Keep Up
A payment account can work perfectly well until the business starts growing. Sales rise and customers arrive from new countries,...
The Hawk Season 2 Updates: Where Did Season 1 End
Netflix’s 2026 series, The Hawk, has been released. It has received a mixed response from the audience in different parts...
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...
Obsession (2026): Release Date, Cast Members, Trailer, Plot, and More
Be Alert: Spoilers Ahead! Are you also a lover of horror shows and looking for upcoming horror movies and series...